

# Alfred Garfall

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8517786/publications.pdf>

Version: 2024-02-01

76  
papers

5,989  
citations

186265

28  
h-index

85541

71  
g-index

77  
all docs

77  
docs citations

77  
times ranked

8692  
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 1289-1301.	1.4	9
2	NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 8-19.	4.9	80
3	History of Autologous SCT Does Not Appear to Blunt the Serologic Response to COVID-19 Vaccination for Patients with Lymphoid Malignancies. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S335-S336.	1.2	0
4	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	1.2	11
5	Teclistamab in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 495-505.	27.0	291
6	Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8007-8007.	1.6	7
7	Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8036-8036.	1.6	2
8	Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8013-8013.	1.6	20
9	Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, e20028-e20028.	1.6	2
10	Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8033-8033.	1.6	2
11	Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8035-8035.	1.6	4
12	Bâ€cell maturation antigen chimeric antigen receptor Tâ€cell reâ€expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitorâ€based combination therapy. <i>British Journal of Haematology</i> , 2021, 193, 851-855.	2.5	6
13	Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8007-8007.	1.6	14
14	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. <i>Nature Medicine</i> , 2021, 27, 1280-1289.	30.7	365
15	Teclistamab, a B-cell maturation antigenâ€CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. <i>Lancet, The</i> , 2021, 398, 665-674.	13.7	138
16	Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking. <i>Clinical Chemistry</i> , 2021, 68, 230-239.	3.2	11
17	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6580-6590.	7.0	15
18	Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy. <i>Journal of Clinical Oncology</i> , 2021, , JCO2101754.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Perfecting CAR Engraftment to a Tee (Cell) through Characterization of Single Cell Transcriptome Product and Understanding Neurotoxicity. <i>Blood</i> , 2021, 138, 1707-1707.	1.4	0
20	Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 161-161.	1.4	13
21	Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients. <i>Blood</i> , 2021, 138, 1757-1757.	1.4	3
22	The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies. <i>Blood</i> , 2021, 138, 253-253.	1.4	2
23	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 896-896.	1.4	29
24	Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas. <i>Blood</i> , 2021, 138, 1438-1438.	1.4	4
25	Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma. <i>American Journal of Hematology</i> , 2020, 95, E28-E30.	4.1	9
26	Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 27-27.	1.4	51
27	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1685-1717.	4.9	138
28	Multitargeted CAR T-cell therapy in multiple myeloma. <i>Lancet Haematology</i> , 2019, 6, e494-e495.	4.6	3
29	Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. <i>Blood Advances</i> , 2019, 3, 2487-2490.	5.2	35
30	Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1946-1955.	1.6	128
31	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 332-344.	0.4	16
32	Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. <i>American Journal of Hematology</i> , 2019, 94, S28-S33.	4.1	35
33	RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. <i>Leukemia</i> , 2019, 33, 2006-2021.	7.2	36
34	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 2812-2815.	5.2	133
35	Trispecific antibodies offer a third way forward for anticancer immunotherapy. <i>Nature</i> , 2019, 575, 450-451.	27.8	27
36	B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. <i>Journal of Clinical Investigation</i> , 2019, 129, 2210-2221.	8.2	513

#	ARTICLE	IF	CITATIONS
37	Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma. <i>Blood</i> , 2019, 134, 1909-1909.	1.4	4
38	Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors. <i>Blood</i> , 2019, 134, 622-622.	1.4	15
39	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 1863-1863.	1.4	13
40	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1154-1165.	4.9	113
41	Carfilzomib-Associated Cardiovascular Adverse Events. <i>JAMA Oncology</i> , 2018, 4, e174519.	7.1	196
42	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018, 3, .	5.0	140
43	Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e337-e338.	0.4	3
44	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1886-1886.	1.4	19
45	PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells. <i>Blood</i> , 2018, 132, 1973-1973.	1.4	13
46	Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2018, 132, 1974-1974.	1.4	10
47	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigenâ€“Matched Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 126-133.	2.0	10
48	The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 27-33.	2.0	9
49	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. <i>Cancer Cell</i> , 2016, 30, 120-135.	16.8	311
50	Cellular and vaccine immunotherapy for multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 521-527.	2.5	16
51	Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. <i>Genes and Development</i> , 2016, 30, 220-232.	5.9	50
52	Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. <i>Cancer Letters</i> , 2016, 371, 117-124.	7.2	59
53	B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study. <i>Blood</i> , 2016, 128, 1147-1147.	1.4	56
54	Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2119-2119.	1.4	12

#	ARTICLE	IF	CITATIONS
55	Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. <i>Blood</i> , 2016, 128, 4548-4548.	1.4	7
56	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. <i>Blood</i> , 2016, 128, 5702-5702.	1.4	31
57	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. <i>Blood</i> , 2016, 128, 974-974.	1.4	28
58	Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. <i>Lancet Haematology</i> , 2015, 2, e408-e416.	4.6	158
59	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. <i>Nature Medicine</i> , 2015, 21, 914-921.	30.7	728
60	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1040-1047.	27.0	511
61	Classifying ultra-high risk smoldering myeloma. <i>Leukemia</i> , 2015, 29, 751-753.	7.2	37
62	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2015, 126, 2022-2022.	1.4	1
63	Association between mobilization regimen and PFS after auto-SCT for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014, 49, 1439-1441.	2.4	4
64	Trials and Tribulations with VH Replacement. <i>Frontiers in Immunology</i> , 2014, 5, 10.	4.8	19
65	High-Throughput Sequencing of Antibody Genes Successfully Identifies Clonal Ig Rearrangements in Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S74-S75.	2.0	0
66	Circulating Multiple Myeloma Cells (CMMCs): A Novel Method for Detection and Molecular Characterization of Peripheral Blood Plasma Cells in Multiple Myeloma Precursor States. <i>Blood</i> , 2014, 124, 2031-2031.	1.4	2
67	Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas. <i>Blood</i> , 2014, 124, 3087-3087.	1.4	13
68	Immunotherapy with chimeric antigen receptors for multiple myeloma. <i>Discovery Medicine</i> , 2014, 17, 37-46.	0.5	22
69	Cellular immunotherapy for plasma cell myeloma. <i>Bone Marrow Transplantation</i> , 2013, 48, 1377-1386.	2.4	8
70	Stem Cell Mobilization With Plerixafor + G-CSF In Comparison To Cyclophosphamide + G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma. <i>Blood</i> , 2013, 122, 3354-3354.	1.4	1
71	Allele Matching At HLA-C or DRB1 Is Associated with Improved Survival After Reduced Intensity Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2012, 120, 2010-2010.	1.4	7
72	Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. <i>Genes and Development</i> , 2011, 25, 2465-2479.	5.9	454

#	ARTICLE	IF	CITATIONS
73	IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. <i>Genes and Development</i> , 2010, 24, 241-255.	5.9	594
74	Inhibition of Cysteine Cathepsin Protease Activity Enhances Chemotherapy Regimens by Decreasing Tumor Growth and Invasiveness in a Mouse Model of Multistage Cancer. <i>Cancer Research</i> , 2007, 67, 7378-7385.	0.9	108
75	Reflections on the Role of the Professionalism Curriculum in Medical School. <i>AMA Journal of Ethics</i> , 2007, 9, 259-261.	0.7	0
76	Promoting Professionalism through an Online Professional Development Portfolio: Successes, Joys, and Frustrations. <i>Academic Medicine</i> , 2007, 82, 1065-1072.	1.6	52